Drug intelligence / Profile preview

ipafricept

Development stage: Phase 1
Lead developer: Mereo BioPharma
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

Ipafricept is a first-in-class recombinant fusion protein composed of the extracellular cysteine-rich domain of the human frizzled family receptor 8 (FZD8) fused to the Fc region of human IgG1. It acts as a decoy receptor that binds and sequesters Wnt ligands, thereby inhibiting Wnt signaling, which is implicated in tumor cell dedifferentiation and cancer stem cell function. Ipafricept was developed for potential antineoplastic activity in solid tumors, including ovarian, pancreatic, and liver cancers. Clinical development was suspended due to dose-limiting bone toxicity observed at higher doses[1][3][4][5][6][7].

Other names: ipafriceptOMP 54F28OMP54F28OMP-54F28Fzd8-FcFzd-8-FcFzd 8-Fc

Targets

Wnt (Wnt ligand)

Beyond the preview

Go deeper on ipafricept.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ipafricept.

Explore the full profile